Pioglitazone (Piog) is a member of thiazolidinediones, insulin-sensitizing drugs, which improve insulin sensitivity and dyslipidemia in type 2 diabetics (Ding et al. 2005). The gene discussed is INS; the disease is metabolic syndrome.